Drug Trial Radar · NCT04984668
A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors
Last checked: Nov 19, 2026Latest source record: Feb 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
216
Planned (sponsor's estimate)
Start
Nov 2, 2021
Primary completion
Apr 2025
Study completion Dec 2025
Sponsor
- Lead sponsor
- Suzhou Kintor Pharmaceutical Inc,Industry
- Sponsor type
- Industry
- Collaborators
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- First posted
- Jul 30, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase Ib is a dose De-escalation study to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary antitumor activity of GT90001 in combination with KN046 in subjects with advanced or refractory hepatocellular carcinoma (HCC), gastric carcinoma (GC) and gastroesophageal junction (GEJ) adenocarcinoma, urothelial carcinoma (UC) and esophageal square cell carcinoma (ESCC). Phase II is to investigate anti-tumor efficacy of GT90001 in combination with KN046 at RP2D in subjects with specific types of tumors. A Simon two-stage design is planned for each indication in order to minimize the number of treated participants if there is minimal efficacy activity in that indication.
Conditions
- Solid Tumor
Interventions
GT90001+KN046Drug
GT90001 7.0mg/Kg, KN046 5mg/Kg
GT90001+KN046Drug
GT90001 7.0mg/Kg , KN046 3mg/Kg
GT90001/KN046Drug
GT90001 4.5mg/Kg / KN046 5mg/Kg
GT90001+KN046Drug
GT90001 4.5mg/Kg, KN046 3mg/Kg
GT90001+KN046Drug
GT90001 3mg/Kg , KN046 3mg/Kg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment-emergent adverse events (TEAEs), treatment-related AEs (TRAEs), serious adverse events (SAEs), Dose Limiting Toxicities (DLTs)Time frame: until progression or death,whichever came first, assessed up to 2 years
- Phase 2 dose (RP2D) of GT90001 in combination with KN046Time frame: after completion of the DLT evaluation of the last subject of Phase Ib, up to 28 days
- Objective response rateTime frame: until progression or death,whichever came first, assessed up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chi-Mei Medical Center
Tainan, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.